Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684176 | 0.94 | TAAR1 (0.66) | TAAR1SMN1; SMN2TSHRMAPTNPC1 | |
| SCHEMBL3645367 | 0.88 | TAAR1 (0.71) | TAAR1SMN1; SMN2MAPTTP53RAB9A | |
| SCHEMBL3643347 | 0.88 | TAAR1 (0.71) | TAAR1SMN1; SMN2TSHRMAPTNPC1 | |
| SCHEMBL3639447 | 0.88 | TAAR1 (0.68) | TAAR1SMN1; SMN2MAPTNPC1TP53 | |
| SCHEMBL3646208 | 0.88 | TAAR1 (0.68) | TAAR1SMN1; SMN2MAPTTP53 | |
| SCHEMBL8079447 | 0.86 | TAAR1 (0.53) | TAAR1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL4254100 | 0.85 | TAAR1 (0.77) | TAAR1NPC1RAB9A | |
| SCHEMBL4247984 | 0.85 | TAAR1 (0.80) | TAAR1SMN1; SMN2MAPTTP53 | |
| SCHEMBL3643138 | 0.85 | TAAR1 (0.68) | TAAR1SMN1; SMN2MAPTTP53 | |
| SCHEMBL3638666 | 0.85 | TAAR1 (0.74) | TAAR1SMN1; SMN2MAPTNPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2182935-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | claimed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | claimed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | claimed |
| US-20240307361-A1 | METHOD FOR DIAGNOSING AND TREATING IRRITABLE BOWEL SYNDROME | Centre for Chinese Herbal Medicine Drug Development Limited (CN) | 2024-09-19 | — | — | US | disclosed |
| US-20240295566-A1 | METHOD FOR DIAGNOSING AND TREATING METABOLIC DISORDERS | Centre for Chinese Herbal Medicine Drug Development Limited (CN) | 2024-09-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307361-A1 | METHOD FOR DIAGNOSING AND TREATING IRRITABLE BOWEL SYNDROME | HRH4, VIPR1, TAAR1 | TAAR1 3/4885SMN1; SMN2 3929/4885TSHR 211/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | TAAR1 97/4885SMN1; SMN2 155/4885TSHR 289/4885 |
| US-20240295566-A1 | METHOD FOR DIAGNOSING AND TREATING METABOLIC DISORDERS | TPH1, GPR119, TAAR1 | TAAR1 3/4885SMN1; SMN2 4137/4885TSHR 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.